In particular, inhibitors specifically designed to interfere SIRT2-GCLC association and subsequent GCLC activation may be utilized to enhance tumor treatment efficacy while decreasing the toxicity to normal cells, which has the potential to ultimately improve the prognosis of cancer patients. This evidence concerns the gene GCLC and neoplasm.